Ross R J, Kirk J M, Tsagarakis S, Trainer P J, Ciccarelli E, Touzel R, Grossman A, Savage M O, Besser G M
Department of Endocrinology, St Bartholomew's Hospital, London, UK.
Clin Endocrinol (Oxf). 1990 Aug;33(2):239-48. doi: 10.1111/j.1365-2265.1990.tb00488.x.
Growth hormone-releasing hormone (GHRH) when given s.c. to GH-insufficient children either as pulses, or once or twice daily, promotes linear growth. These treatment regimens, however, are not ideal as they require frequent drug administration and a significant proportion of patients do not show improved growth. We have now investigated the GH response to a nocturnal s.c. infusion of GHRH (1-29)NH2, at two dosages, 5 and 10 micrograms/kg/h, in a group of five GH-insufficient children. The s.c. infusion of GHRH between 2100 h and 0600 h augmented nocturnal pulsatile GH release in all five children. There was a dose-dependent response for the GH area under the curve (AUC), and mean total GH concentration. The AUC for GH was significantly greater after the 10 than 5 micrograms/kg/h GHRH which in turn was greater than that after placebo; mean (SD) AUC: 14816 (3978), 8125 (1931), 3032 (1582) mU min/l respectively (P less than 0.01 and P less than 0.05). There was no significant change in the number of GH pulses during the 9-h infusions when the subjects were infused with GHRH 10 or 5 micrograms/kg/h compared to placebo, and they occurred at similar times although the number of pulses tended to be greater after GHRH; the mean (SD) numbers of GH pulses were 5.0 (0.7), 3.8 (0.8), 3.2 (0.8), respectively. There was however a significant rise in the mean baseline GH concentration in all patients during the infusion of GHRH 10 micrograms/kg/h compared to placebo, but not with 5 micrograms/kg/h. Thus, GHRH(1-29)NH2 given s.c. augmented nocturnal pulsatile GH release in GH-insufficient children but it also increased baseline GH secretion. These results suggest that a sustained release preparation of GHRH could be a potential treatment for GH-insufficient children, and that a dose of 5 micrograms/kg/h would promote pulsatile GH release, but that at higher dosage it may also raise basal GH secretion.
生长激素释放激素(GHRH)皮下注射给生长激素缺乏的儿童,无论是脉冲式给药,还是每日一次或两次,均可促进线性生长。然而,这些治疗方案并不理想,因为它们需要频繁给药,而且相当一部分患者的生长情况并未得到改善。我们现在研究了一组5名生长激素缺乏儿童在夜间皮下输注两种剂量(5和10微克/千克/小时)的GHRH(1-29)NH2时的生长激素反应。在21:00至06:00期间皮下输注GHRH可增强所有5名儿童夜间的脉冲式生长激素释放。生长激素曲线下面积(AUC)和平均总生长激素浓度呈剂量依赖性反应。10微克/千克/小时GHRH后的生长激素AUC显著大于5微克/千克/小时的,而5微克/千克/小时的又大于安慰剂后的;平均(标准差)AUC分别为14816(3978)、8125(1931)、3032(1582)毫单位·分钟/升(P<0.01和P<0.05)。与安慰剂相比,当受试者接受10或5微克/千克/小时GHRH 9小时输注时,生长激素脉冲数无显著变化,且脉冲出现时间相似,尽管GHRH后脉冲数往往更多;生长激素脉冲的平均(标准差)数分别为5.0(0.7)、3.8(0.8)、3.2(0.8)。然而,与安慰剂相比,在输注10微克/千克/小时GHRH期间,所有患者的平均基础生长激素浓度均显著升高,但5微克/千克/小时时未升高。因此,皮下注射GHRH(1-29)NH2可增强生长激素缺乏儿童夜间的脉冲式生长激素释放,但也会增加基础生长激素分泌。这些结果表明,GHRH缓释制剂可能是治疗生长激素缺乏儿童的一种潜在方法,5微克/千克/小时的剂量可促进脉冲式生长激素释放,但更高剂量可能也会提高基础生长激素分泌。